The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate (Paricalcitol)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01163162|
Recruitment Status : Completed
First Posted : July 15, 2010
Results First Posted : May 21, 2013
Last Update Posted : May 21, 2013
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease||Drug: Paricalcitol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||June 2011|
After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
2 mcg oral Paricalcitol once per day for 7 days
Other Name: Zemplar
- 24-hour Urine Creatinine Excretion Rate [ Time Frame: 1 Week ]We expect the 24 hour urine creatinine excretion rate to show no differences between groups.
- Creatinine Clearance [ Time Frame: 1 Week ]The primary outcome variable will be creatinine clearance. Subject will be used as random variable and maximal likelihood estimation methods will be used. We expect no differences between periods.
- Serum Creatinine [ Time Frame: 1 Week ]We expect serum creatinine to confirm the results of creatinine clearance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01163162
|United States, Indiana|
|Roudebush VA Medical Center|
|Indianapolis, Indiana, United States, 46202|
|Principal Investigator:||Rajiv Agarwal, MD||Indiana University|